Sophie Lawrance quoted on Global Competition Review


Sophie Lawrance spoke to Global Competition Review last week about the CMA decision to accept Essential Pharma’s commitments to keep its Priadel drug on the market. This was the first new pharma case that the CMA had announced for some considerable time, and an interesting development even if it looks like “a score draw”.

You can read the full article here:

Sophie Lawrance


Related Articles